Abdullah Husain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdullah Husain has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Irene Oi-Lin Ng
Department of Pathology, The University of Hong Kong, Hong Kong, China
4 shared publications - Daniel Wai-Hung Ho
Department of Pathology, The University of Hong Kong, Hong Kong, China
2 shared publications - Karen Man-Fong Sze
Department of Pathology, the University of Hong Kong, Pokfulam, Hong Kong
2 shared publications - Yung-Tuen Chiu
Cancer Biology Group, Department of Anatomy and Departments of 2 Pathology and 3 Surgery, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
2 shared publications - Albert Chi Yan Chan
Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
1 shared publication - Eliana Mary Senires Suarez
Department of Pathology, The University of Hong Kong, Hong Kong
1 shared publication
Latest Publications
- Open Access
- 10 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (2) , 3287-3296
Prospective analysis on the outcomes of histotripsy for primary and metastatic liver tumors
Background: Histotripsy is an innovative, non-invasive ultrasound-based technology that mechanically disrupts liver tumor tissues at the cellular level through acoustic cavitation. It offered precise tissue destruction with minimal collateral damage. This study evaluated the safety and efficacy of this novel treatment through clinical and biomolecular analysis. Methods: From August to 30 December 2024 patients with malignant liver cancers, Child-Pugh A liver function, and tumors <10 cm were recruited. Treatments were performed under general anesthesia using histotripsy with tailored approaches for left and right liver tumors. Technical success and treatment efficacy were assessed by contrast-enhanced MRI at 36 hours and 1 month post-procedure. Complications were classified by Clavien-Dindo criteria. Plasma cytokine profiles were analyzed pre-treatment, at 1-day, and 1-month post-treatment. A cytokine score predictive of clinical outcomes was derived via Least Absolute Shrinkage and Selection Operator regression and Receiver Operating Characteristic analysis. Results: A total of 19 patients (63.3%) had hepatocellular carcinoma while the remaining 11 patients had liver metastases from different origins including colorectal, pancreas, breast, and thyroid. A total of sixty tumors with a median tumor diameter of 1.8 cm and a median tumor number per patient of 2 were treated. The 36-hour technical success rate was 95% and 1-month efficacy rate was 82.5%. Procedure-related complications were mild, including transient fever and abdominal discomfort controlled by analgesics; no grade III or above complications occurred. Cytokine profiling revealed a significant systemic inflammatory response at 1-day post-treatment, notably increased Interleukin 6 (IL-6). A four-cytokine panel (IL-7, IL-6, IL-1α, CXCL1) generated a cytokine score that strongly predicted complete tumor response (area under the curve = 0.955). Higher cytokine scores correlated with greater treatment volume and elevated liver enzymes indicative of an immunomodulatory effect. Conclusion: Histotripsy was a safe and effective non-invasive treatment for liver tumors, demonstrating promising clinical outcomes and systemic immune activation. These findings supported further investigation into its long-term efficacy and potential synergy with immunotherapy.
- 10 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (2) , 3287-3296
Open AccessProspective analysis on the outcomes of histotripsy for primary and metastatic liver tumors
Background: Histotripsy is an innovative, non-invasive ultrasound-based technology that mechanically disrupts liver tumor tissues at the cellular level through acoustic cavitation. It offered precise tissue destruction with minimal collateral damage. This study evaluated the safety and efficacy of this novel treatment through clinical and biomolecular analysis. Methods: From August to 30 December 2024 patients with malignant liver cancers, Child-Pugh A liver function, and tumors <10 cm were recruited. Treatments were performed under general anesthesia using histotripsy with tailored approaches for left and right liver tumors. Technical success and treatment efficacy were assessed by contrast-enhanced MRI at 36 hours and 1 month post-procedure. Complications were classified by Clavien-Dindo criteria. Plasma cytokine profiles were analyzed pre-treatment, at 1-day, and 1-month post-treatment. A cytokine score predictive of clinical outcomes was derived via Least Absolute Shrinkage and Selection Operator regression and Receiver Operating Characteristic analysis. Results: A total of 19 patients (63.3%) had hepatocellular carcinoma while the remaining 11 patients had liver metastases from different origins including colorectal, pancreas, breast, and thyroid. A total of sixty tumors with a median tumor diameter of 1.8 cm and a median tumor number per patient of 2 were treated. The 36-hour technical success rate was 95% and 1-month efficacy rate was 82.5%. Procedure-related complications were mild, including transient fever and abdominal discomfort controlled by analgesics; no grade III or above complications occurred. Cytokine profiling revealed a significant systemic inflammatory response at 1-day post-treatment, notably increased Interleukin 6 (IL-6). A four-cytokine panel (IL-7, IL-6, IL-1α, CXCL1) generated a cytokine score that strongly predicted complete tumor response (area under the curve = 0.955). Higher cytokine scores correlated with greater treatment volume and elevated liver enzymes indicative of an immunomodulatory effect. Conclusion: Histotripsy was a safe and effective non-invasive treatment for liver tumors, demonstrating promising clinical outcomes and systemic immune activation. These findings supported further investigation into its long-term efficacy and potential synergy with immunotherapy.
- Open Access
- 13 September 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (6) , 1805-1821
Disparity landscapes of viral-induced structural variations in HCC: Mechanistic characterization and functional implications
Oncoviruses can integrate into the host genome and cause tumorigenesis. In particular, hepatitis B virus (HBV) infection accounts for more than 50% of hepatocellular carcinoma (HCC) worldwide. We revealed the global geographical disparity of HBV integration that the landscape of HBV integration between HCC tumor and non-tumorous liver varied in regional cohorts, suggesting the different degrees of clonal enrichment. Most HBV integrations were positionally enriched at telomeres and centromeres (T&C) and they highlighted the novel co-involvement of HBV integration, which likely introduces genomic instability in HCC development. This was confirmed by phospho-H2AX staining. We constructed a large meta-cohort of multiple ethnicities to refine the landscape of HBV integration. This enables the gene set/family level exploration. As TERT is the most frequently integrated gene, we further investigated the underlying mechanistic modulation of TERT transcription activation and revealed the concurrent influence by the orientation and relative distance of HBV integration. Additionally, clonal disparity of HBV integration was observed among patients and the higher level of clonal disparity score can indicate poor patients’ prognostication. Taken together, our study uncovered the different levels of clonal enrichment of HBV integration, mechanistic insights, and prognostic biomarker signature, to strengthen our understanding in HBV-associated hepatocarcinogenesis. Export
- 13 September 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (6) , 1805-1821
Open AccessDisparity landscapes of viral-induced structural variations in HCC: Mechanistic characterization and functional implications
Oncoviruses can integrate into the host genome and cause tumorigenesis. In particular, hepatitis B virus (HBV) infection accounts for more than 50% of hepatocellular carcinoma (HCC) worldwide. We revealed the global geographical disparity of HBV integration that the landscape of HBV integration between HCC tumor and non-tumorous liver varied in regional cohorts, suggesting the different degrees of clonal enrichment. Most HBV integrations were positionally enriched at telomeres and centromeres (T&C) and they highlighted the novel co-involvement of HBV integration, which likely introduces genomic instability in HCC development. This was confirmed by phospho-H2AX staining. We constructed a large meta-cohort of multiple ethnicities to refine the landscape of HBV integration. This enables the gene set/family level exploration. As TERT is the most frequently integrated gene, we further investigated the underlying mechanistic modulation of TERT transcription activation and revealed the concurrent influence by the orientation and relative distance of HBV integration. Additionally, clonal disparity of HBV integration was observed among patients and the higher level of clonal disparity score can indicate poor patients’ prognostication. Taken together, our study uncovered the different levels of clonal enrichment of HBV integration, mechanistic insights, and prognostic biomarker signature, to strengthen our understanding in HBV-associated hepatocarcinogenesis. Export
- Open Access
- 13 January 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (5) , 1368-1383
Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC
Background and Aims: Understanding the mechanisms of HCC progression and metastasis is crucial to improve early diagnosis and treatment. This study aimed to identify key molecular targets involved in HCC metastasis. Approach and Results: Using whole-transcriptome sequencing of patients’ HCCs, we identified and validated midline 1 interacting protein 1 (MID1IP1) as one of the most significantly upregulated genes in metastatic HCCs, suggesting its potential role in HCC metastasis. Clinicopathological correlation demonstrated that MID1IP1 upregulation significantly correlated with more aggressive tumor phenotypes and poorer patient overall survival rates. Functionally, overexpression of MID1IP1 significantly promoted the migratory and invasive abilities and enhanced the sphere-forming ability and expression of cancer stemness-related genes of HCC cells, whereas its stable knockdown abrogated these effects. Perturbation of MID1IP1 led to significant tumor shrinkage and reduced pulmonary metastases in an orthotopic liver injection mouse model and reduced pulmonary metastases in a tail-vein injection model in vivo. Mechanistically, SP1 transcriptional factor was found to be an upstream driver of MID1IP1 transcription. Furthermore, transcriptomic sequencing on MID1IP1-overexpressing HCC cells identified FOS-like 1 (FRA1) as a critical downstream mediator of MID1IP1. MID1IP1 upregulated FRA1 to subsequently promote its transcriptional activity and extracellular matrix degradation activity of matrix metalloproteinase MMP9, while knockdown of FRA1 effectively abolished the MID1IP1-induced migratory and invasive abilities. Conclusions: Our study identified MID1IP1 as a regulator in promoting FRA1-mediated-MMP9 signaling and demonstrated its role in HCC metastasis. Targeting MID1IP1-mediated FRA1 pathway may serve as a potential therapeutic strategy against HCC progression.
- 13 January 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (5) , 1368-1383
Open AccessMidline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC
Background and Aims: Understanding the mechanisms of HCC progression and metastasis is crucial to improve early diagnosis and treatment. This study aimed to identify key molecular targets involved in HCC metastasis. Approach and Results: Using whole-transcriptome sequencing of patients’ HCCs, we identified and validated midline 1 interacting protein 1 (MID1IP1) as one of the most significantly upregulated genes in metastatic HCCs, suggesting its potential role in HCC metastasis. Clinicopathological correlation demonstrated that MID1IP1 upregulation significantly correlated with more aggressive tumor phenotypes and poorer patient overall survival rates. Functionally, overexpression of MID1IP1 significantly promoted the migratory and invasive abilities and enhanced the sphere-forming ability and expression of cancer stemness-related genes of HCC cells, whereas its stable knockdown abrogated these effects. Perturbation of MID1IP1 led to significant tumor shrinkage and reduced pulmonary metastases in an orthotopic liver injection mouse model and reduced pulmonary metastases in a tail-vein injection model in vivo. Mechanistically, SP1 transcriptional factor was found to be an upstream driver of MID1IP1 transcription. Furthermore, transcriptomic sequencing on MID1IP1-overexpressing HCC cells identified FOS-like 1 (FRA1) as a critical downstream mediator of MID1IP1. MID1IP1 upregulated FRA1 to subsequently promote its transcriptional activity and extracellular matrix degradation activity of matrix metalloproteinase MMP9, while knockdown of FRA1 effectively abolished the MID1IP1-induced migratory and invasive abilities. Conclusions: Our study identified MID1IP1 as a regulator in promoting FRA1-mediated-MMP9 signaling and demonstrated its role in HCC metastasis. Targeting MID1IP1-mediated FRA1 pathway may serve as a potential therapeutic strategy against HCC progression.
- Open Access
- 20 May 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (3) , 880-882
Reply to: ‘EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma’
- 20 May 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (3) , 880-882
Open AccessReply to: ‘EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma’